Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.04 USD | -9.79% | -13.39% | -5.30% |
Mar. 18 | Allogene Therapeutics, Inc.(NasdaqGS:ALLO) added to S&P Biotechnology Select Industry Index | CI |
Mar. 15 | Allogene Therapeutics Files $500 Million Mixed Shelf | MT |
Evolution of the average Target Price on Allogene Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Allogene Therapeutics, Inc.
HC Wainwright | |
B. Riley | |
JMP Securities | |
Citigroup | |
JPMorgan Chase | |
Truist Securities | |
RBC Capital Markets | |
Stifel Nicolaus | |
Bernstein | |
Oppenheimer | |
Goldman Sachs | |
Baird | |
EF Hutton | |
BofA Securities | |
Raymond James | |
Guggenheim | |
Cowen | |
SMBC Nikko | |
Roth Capital Partners | |
Jefferies & Co. |
EPS Revisions
- Stock Market
- Equities
- ALLO Stock
- Consensus Allogene Therapeutics, Inc.